Exenatide 3.5μg/mL solution for subcutaneous injection, Potassium canrenoate 5mg/mL solution for intravenous injection, Amodiaquine+Glibenclamide (10mg+0.1mg) /5mL oral suspension, Amodiaquine 2mg/mL solution for intravenous injection, Potassium canrenoate 25mg/5mL oral suspension
GEN-100
Phase 2 small_molecule active
Quick answer
Exenatide 3.5μg/mL solution for subcutaneous injection, Potassium canrenoate 5mg/mL solution for intravenous injection, Amodiaquine+Glibenclamide (10mg+0.1mg) /5mL oral suspension, Amodiaquine 2mg/mL solution for intravenous injection, Potassium canrenoate 25mg/5mL oral suspension for Acute Ischemic Stroke is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Acute Ischemic Stroke
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active